感染艾滋病毒孕妇中多拉韦林耐药性的基线调查。 - Suppr

Baseline survey of doravirine resistance among pregnant women with HIV.

作者信息

Sfalcin Javier Alejandro, Cecchini Diego, Zapiola Ines, Gómez Alan, Fernández-Giuliano Silvina, Rodríguez Claudia, Mammana Lilia, Seravalle Analia, Fay Fabián, Belén-Bouzas María

机构信息

Molecular biology area, CIBIC Laboratorios, Argentina.

Infectious Diseases Unit, Hospital Cosme Argerich, Argentina.

出版信息

Rev Esp Quimioter. 2025 Mar 3;38(2):139-141. doi: 10.37201/req/107.2024. Epub 2025 Feb 6.

DOI:10.37201/req/107.2024

PMID:39927586

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11894565/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/77e2/11894565/03379e7328e1/revespquimioter-38-139-g001.jpg

相似文献

Baseline survey of doravirine resistance among pregnant women with HIV.

Rev Esp Quimioter. 2025 Mar 3;38(2):139-141. doi: 10.37201/req/107.2024. Epub 2025 Feb 6.

Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial.

Lancet HIV. 2024 Jun;11(6):e369-e379. doi: 10.1016/S2352-3018(24)00031-6. Epub 2024 May 8.

DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine.

J Antimicrob Chemother. 2024 Aug 1;79(8):1974-1984. doi: 10.1093/jac/dkae194.

Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa.

J Int AIDS Soc. 2021 May;24(5):e25706. doi: 10.1002/jia2.25706.

Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

Lancet HIV. 2024 Jun;11(6):e357-e368. doi: 10.1016/S2352-3018(24)00030-4. Epub 2024 May 8.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.

Lancet HIV. 2020 Jan;7(1):e16-e26. doi: 10.1016/S2352-3018(19)30336-4. Epub 2019 Nov 15.

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance.

AIDS Res Ther. 2023 Feb 7;20(1):8. doi: 10.1186/s12981-023-00503-5.

Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.

J Antimicrob Chemother. 2023 Aug 2;78(8):1921-1928. doi: 10.1093/jac/dkad184.

In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.

J Antimicrob Chemother. 2021 Jan 1;76(1):130-134. doi: 10.1093/jac/dkaa401.

Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.

Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0121621. doi: 10.1128/AAC.01216-21. Epub 2021 Sep 27.

本文引用的文献

Pretreatment HIV-1 Resistance in Argentina: Results from the Second Surveillance Study Following World Health Organization Guidelines (2019).

AIDS Res Hum Retroviruses. 2024 Aug;40(8):464-470. doi: 10.1089/AID.2023.0083. Epub 2024 Apr 3.

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance.

AIDS Res Ther. 2023 Feb 7;20(1):8. doi: 10.1186/s12981-023-00503-5.

Impacts of HIV-1 Subtype Diversity on Long-Term Clinical Outcomes in Antiretroviral Therapy in Guangxi, China.

J Acquir Immune Defic Syndr. 2022 Apr 15;89(5):583-591. doi: 10.1097/QAI.0000000000002906.

Reverse transcriptase and protease inhibitors mutational viral load in HIV infected pregnant women with transmitted drug resistance in Argentina.

Rev Esp Quimioter. 2021 Aug;34(4):371-375. doi: 10.37201/req/022.2021. Epub 2021 Jun 4.

Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping.

J Antimicrob Chemother. 2020 Dec 1;75(12):3517-3524. doi: 10.1093/jac/dkaa349.

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.

J Acquir Immune Defic Syndr. 2019 Dec 1;82(4):e47-e49. doi: 10.1097/QAI.0000000000002153.

A MiSeq-HyDRA platform for enhanced HIV drug resistance genotyping and surveillance.

Sci Rep. 2019 Jun 20;9(1):8970. doi: 10.1038/s41598-019-45328-3.

[HIV-1 resistance to antiretroviral drugs in pregnant women from Buenos Aires metropolitan area].

Medicina (B Aires). 2016;76(6):349-354.

Pretreatment HIV-1 drug resistance in Argentina: results from a surveillance study performed according to WHO-proposed new methodology in 2014-15.

J Antimicrob Chemother. 2017 Feb;72(2):504-510. doi: 10.1093/jac/dkw445. Epub 2016 Oct 26.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Baseline survey of doravirine resistance among pregnant women with HIV.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献